vs
Fiverr International Ltd.（FVRR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Fiverr International Ltd.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$287.8M vs $207.3M），Fiverr International Ltd.净利率更高（1.9% vs -62.0%，领先63.9%），Fiverr International Ltd.自由现金流更多（$52.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 29.5%）
Fiverr International Ltd.运营全球在线自由职业服务平台，连接160余个国家的企业客户与独立创作者，提供数字营销、平面设计、编程、文案撰写、视频剪辑等多领域专业服务，满足各类客户灵活的按需用工需求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FVRR vs RARE — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $287.8M | $207.3M |
| 净利润 | $5.4M | $-128.6M |
| 毛利率 | 82.5% | — |
| 营业利润率 | -3.5% | -54.7% |
| 净利率 | 1.9% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $207.3M | ||
| Q3 25 | $287.8M | $159.9M | ||
| Q2 25 | $188.2M | $166.5M | ||
| Q1 25 | $93.5M | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $269.9M | $139.5M | ||
| Q2 24 | $177.3M | $147.0M | ||
| Q1 24 | $88.0M | $108.8M |
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $5.4M | $-180.4M | ||
| Q2 25 | $4.1M | $-115.0M | ||
| Q1 25 | $788.0K | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-1.0M | $-133.5M | ||
| Q2 24 | $-4.0M | $-131.6M | ||
| Q1 24 | $-4.3M | $-170.7M |
| Q4 25 | — | — | ||
| Q3 25 | 82.5% | — | ||
| Q2 25 | 83.3% | — | ||
| Q1 25 | 83.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 82.8% | — | ||
| Q2 24 | 82.4% | — | ||
| Q1 24 | 82.2% | — |
| Q4 25 | — | -54.7% | ||
| Q3 25 | -3.5% | -106.9% | ||
| Q2 25 | -3.4% | -64.8% | ||
| Q1 25 | -4.4% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | -5.0% | -94.6% | ||
| Q2 24 | -6.3% | -79.1% | ||
| Q1 24 | -8.1% | -151.9% |
| Q4 25 | — | -62.0% | ||
| Q3 25 | 1.9% | -112.8% | ||
| Q2 25 | 2.2% | -69.0% | ||
| Q1 25 | 0.8% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -0.4% | -95.7% | ||
| Q2 24 | -2.3% | -89.5% | ||
| Q1 24 | -4.9% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $362.6M | $-80.0M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | $133.5M | $202.5M | ||
| Q2 25 | $578.4M | $176.3M | ||
| Q1 25 | $133.5M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $183.7M | $150.6M | ||
| Q2 24 | $183.7M | $480.7M | ||
| Q1 24 | $183.7M | $112.3M |
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $362.6M | $9.2M | ||
| Q2 25 | $404.9M | $151.3M | ||
| Q1 25 | $362.6M | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $355.8M | $346.8M | ||
| Q2 24 | $355.8M | $432.4M | ||
| Q1 24 | $355.8M | $140.3M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $52.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 18.1% | -48.6% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 9.81× | — |
| 过去12个月自由现金流最近4个季度 | $124.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $53.0M | $-91.4M | ||
| Q2 25 | $42.2M | $-108.3M | ||
| Q1 25 | $21.2M | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $10.9M | $-67.0M | ||
| Q2 24 | $32.2M | $-77.0M | ||
| Q1 24 | $21.2M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $52.1M | $-92.7M | ||
| Q2 25 | $41.5M | $-110.7M | ||
| Q1 25 | $20.8M | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $10.6M | $-68.6M | ||
| Q2 24 | $31.5M | $-79.0M | ||
| Q1 24 | $20.8M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | 18.1% | -58.0% | ||
| Q2 25 | 22.0% | -66.5% | ||
| Q1 25 | 22.3% | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 3.9% | -49.2% | ||
| Q2 24 | 17.8% | -53.7% | ||
| Q1 24 | 23.7% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.4% | 1.4% | ||
| Q1 24 | 0.4% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 9.81× | — | ||
| Q2 25 | 10.40× | — | ||
| Q1 25 | 26.90× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVRR
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
